Dr. Esham has worked for BIO for 15 years and in public health policy for more than 23 years. At BIO she focuses on developing policies that promote investment in and development of innovative medicines and vaccines. She works with BIO’s small and emerging biotech companies (which comprise approximately 90 percent of BIO’s membership) to grow, thrive, and develop cutting edge innovation. She works with BIO member companies to create and support a patient-centric, inclusive and effective clinical development paradigm in the U.S. and in key countries around the world. And lastly, she works to remove regulatory barriers that negatively impact the flow of capital to the research and development of innovative medicines and vaccines and promote policies that will support investment and development of next-generation medical breakthroughs.
- Previous experience: Dutko Worldwide
- Boards and Steering Committees: Alliance for a Stronger FDA, Eshelman Institute for Innovation, Innovation Equity Forum
- Published papers in peer-reviewed scientific journals on water quality, marine microbial ecology, and bacterial phylogeny
- Education: The University of Georgia (Ph.D., Microbiology); The University of North Carolina Wilmington (Master of Science, Marine Biology); University of Kentucky
